Skip to main content

Table 3 Transplant outcomes of the intervention group according to the number of feedback messages generated

From: ICT-based adherence monitoring in kidney transplant recipients: a randomized controlled trial

 

Feedback ≥1 (n = 13)

No feedback (n = 38)

p value

Drug levels

 TAC trough level, ng/mL

5.1 ± 1.2

5.3 ± 1.1

0.574

 TAC CVa

29.4 ± 16.3

22.1 ± 12.0

0.155

 MPA trough level, μg/mL

2.4 ± 1.0

2.9 ± 1.8

0.332

 MPA CVa

36.6 ± 24.8

38.3 ± 14.3

0.754

eGFR

 4 weeks

71.5 ± 21.9

66.6 ± 16.9

0.474

 8 weeks

69.8 ± 22.7

67.3 ± 18.8

0.720

 12 weeks

66.4 ± 21.0

66.8 ± 19.1

0.946

 16 weeks

66.6 ± 19.4

67.9 ± 16.9

0.829

 20 weeks

66.9 ± 22.2

66.1 ± 16.6

0.914

 24 weeks

65.7 ± 23.5

65.0 ± 17.4

0.928

Number of events, n (%)

 De novo anti-HLA antibodies

1 (7.7)

2 (5.3)

0.748

 BK viremia

0 (0)

1 (2.6)

0.555

 BPAR

 

 DCGL

 
  1. Values are shown as mean ± standard deviation or number (%)
  2. BPAR Biopsy-proven acute rejection, CV Coefficient of variation, DCGL Death-censored graft loss, eGFR estimated glomerular filtration rate, HLA Human leukocyte antigen, MPA Mycophenolic acid, TAC Tacrolimus
  3. aCV = (standard deviation/mean) × 100%